These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19016738)

  • 1. A substrate peptide for the FLT3 receptor tyrosine kinase.
    Böhmer FD; Uecker A
    Br J Haematol; 2009 Jan; 144(1):127-30. PubMed ID: 19016738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells.
    Grafone T; Palmisano M; Nicci C; Martelli AM; Emanuela O; Storti S; Baccarani M; Martinelli G
    Hematol Oncol; 2008 Sep; 26(3):159-66. PubMed ID: 18383555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
    Sritana N; Auewarakul CU
    Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
    Youssoufian H; Rowinsky EK; Tonra J; Li Y
    Cancer; 2010 Feb; 116(4 Suppl):1013-7. PubMed ID: 20127944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation.
    Razumovskaya E; Masson K; Khan R; Bengtsson S; Rönnstrand L
    Exp Hematol; 2009 Aug; 37(8):979-89. PubMed ID: 19477218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.
    Cheng Y; Paz K
    IDrugs; 2008 Jan; 11(1):46-56. PubMed ID: 18175263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New therapeutic option for leukemia patients, with FLT3/Aurora kinase inhibitor, KW-2449: strategy and comparison with other kinase inhibitors].
    Shiotsu Y
    Rinsho Ketsueki; 2008 Aug; 49(8):641-9. PubMed ID: 18800614
    [No Abstract]   [Full Text] [Related]  

  • 8. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
    Stone RM; De Angelo J; Galinsky I; Estey E; Klimek V; Grandin W; Lebwohl D; Yap A; Cohen P; Fox E; Neuberg D; Clark J; Gilliland DG; Griffin JD
    Ann Hematol; 2004; 83 Suppl 1():S89-90. PubMed ID: 15124689
    [No Abstract]   [Full Text] [Related]  

  • 9. FLT3 inhibition in acute myeloid leukaemia.
    Knapper S
    Br J Haematol; 2007 Sep; 138(6):687-99. PubMed ID: 17655729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational drugs targeting FLT3 for leukemia.
    Ustun C; DeRemer DL; Jillella AP; Bhalla KN
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can FLT3 inhibitors overcome resistance in AML?
    Tam WF; Gary Gilliland D
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival.
    Masson K; Liu T; Khan R; Sun J; Rönnstrand L
    Br J Haematol; 2009 Jul; 146(2):193-202. PubMed ID: 19438505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity.
    Chen Y; Guo Y; Han J; Ho WT; Li S; Fu X; Zhao ZJ
    J Hematol Oncol; 2012 Jul; 5():39. PubMed ID: 22800464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of EphA4 receptor tyrosine kinase substrate specificity using peptide-based arrays.
    Warner N; Wybenga-Groot LE; Pawson T
    FEBS J; 2008 May; 275(10):2561-73. PubMed ID: 18422655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [FLT3 inhibitor monotherapy for refractory acute myeloid leukemia: a case report].
    Pan J; Yang JF; Tong CR
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Nov; 16(11):1168-9. PubMed ID: 25406566
    [No Abstract]   [Full Text] [Related]  

  • 16. Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents.
    Furet P; Bold G; Meyer T; Roesel J; Guagnano V
    J Med Chem; 2006 Jul; 49(15):4451-4. PubMed ID: 16854049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
    Lee SH; Paietta E; Racevskis J; Wiernik PH
    Am J Hematol; 2009 Oct; 84(10):701-2. PubMed ID: 19714594
    [No Abstract]   [Full Text] [Related]  

  • 18. FLT3 Inhibitors in the Treatment of AML.
    Gilliland DG
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):708-10. PubMed ID: 16163256
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor.
    Riccioni R; Diverio D; Riti V; Buffolino S; Mariani G; Boe A; Cedrone M; Ottone T; Foà R; Testa U
    Br J Haematol; 2009 Feb; 144(3):376-87. PubMed ID: 19036083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.
    Muranyi AL; Dedhar S; Hogge DE
    Exp Hematol; 2009 Apr; 37(4):450-60. PubMed ID: 19302919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.